The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Changes In Market Value Are Expected For The Pediatric Brain Tumors Market Over The 2026–2030 Period?
The market for pediatric brain tumors has demonstrated robust expansion recently. This market is projected to expand from $1.4 billion in 2025 to $1.49 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.9%. Historically, this growth has been driven by factors such as a lack of comprehensive awareness regarding pediatric brain tumors, a continued dependence on traditional therapeutic approaches, infrequent utilization of sophisticated imaging methods, an inadequacy of specialized pediatric neuro-oncology facilities, and restricted access to targeted and immunotherapy interventions.
The market for pediatric brain tumors is projected to experience robust expansion over the coming years. This market is anticipated to reach $1.93 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.6%. This expansion during the forecast period is driven by factors such as the increasing occurrence of pediatric brain tumors, greater uptake of precision medicine, enhanced integration of AI and digital imaging in diagnostic processes, a heightened emphasis on individualized treatment strategies, and increased financial support for pediatric neuro-oncology research. Key trends expected during this period involve the wider embrace of precision medicine specifically for pediatric brain tumors, a growing incorporation of digital imaging and AI-powered diagnostics, an expanding application of targeted therapies and immunotherapies, a greater emphasis on surgical methods that are less invasive, and a surge in investment directed towards pediatric neuro-oncology research.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21248&type=smp
Which Major Drivers Are Influencing The Expansion Of The Pediatric Brain Tumors Market?
The expanding need for personalized medicine is projected to stimulate the growth of the pediatric brain tumors market moving forward. Personalized medicine is a healthcare approach that individualizes treatments and medical decisions based on a person’s genetic makeup, lifestyle, and specific health needs. The rise in demand for personalized medicine is attributed to advancements in genetic research, improved diagnostic tools, and the potential for more effective and targeted treatments. By tailoring therapies to the child’s specific tumor type, mutation, and response, personalized medicine enables targeted interventions that are more efficacious and cause less damage to healthy tissue, thereby enhancing outcomes and reducing side effects. For instance, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, an increase from six in 2022. Thus, the increasing demand for personalized medicine is propelling the pediatric brain tumor market’s expansion.
How Is The Pediatric Brain Tumors Market Organized By Segment Classification?
The pediatric brain tumors market covered in this report is segmented –
1) By Type: Gliomas, Mixed Neuronal-Glial Tumors, Embryonal Tumors, Choroid Plexus Papilloma Or Carcinoma, Tumors Arising From Non-Neuroepithelial Tissue, Meningeal Tumors
2) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy
3) By Diagnosis Method: Imaging Techniques, Biopsy, Neurological Exam, Lumbar Puncture
4) By Age Group: Infants, Toddlers, Children, Adolescents
5) By Application: Hospitals And Clinics, Medical Research Centers, Academic Institutes, Other Applications
Subsegments:
1) By Gliomas: Low-Grade Gliomas, High-Grade Gliomas
2) By Mixed Neuronal-Glial Tumors: Gangliogliomas, Dysembryoplastic Neuroepithelial Tumors (DNET)
3) By Embryonal Tumors: Medulloblastoma, Atypical Teratoid Rhabdoid Tumor (ATRT), Primitive Neuroectodermal Tumors (PNET)
4) By Choroid Plexus Papilloma Or Carcinoma: Choroid Plexus Papilloma, Choroid Plexus Carcinoma
5) By Tumors Arising From Non-Neuroepithelial Tissue: Rhabdomyosarcoma, Ewing’s Sarcoma
6) By Meningeal Tumors: Meningiomas, Hemangiopericytomas
Which Trends Are Shaping The Pediatric Brain Tumors Market?
Leading companies in the pediatric brain tumors market are concentrating on developing advanced treatments, such as type II RAF inhibitors, to enhance targeted therapies and improve patient outcomes. These inhibitors represent targeted therapies focused on suppressing RAF kinases, particularly those with mutations that drive tumor growth. They are designed to target abnormal RAF protein structures found in certain pediatric low-grade glioma (pLGG) subtypes, effectively blocking the faulty signaling pathways contributing to tumor cell proliferation and survival. For instance, in April 2024, Day One Biopharmaceuticals, a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for OJEMDA (tovorafenib) for the treatment of relapsed or refractory pediatric low-grade glioma (pLGG) in patients aged 6 months and older with specific BRAF alterations. This approval establishes OJEMDA as the first FDA-approved therapy targeting BRAF fusions or mutations in this patient population. The approval is based on the reported overall response rate of 51% from the FIREFLY-1 clinical trial, which assessed the drug’s efficacy in this indication. It is specifically intended for children with brain tumors that have not responded to previous treatments.
Who Are The Industry Participants Involved In The Pediatric Brain Tumors Market?
Major companies operating in the pediatric brain tumors market are Bayer AG, Novartis AG, Roche Holding AG, Takeda Pharmaceutical Company, UCLA Health, Novocure, Blueprint Medicines, Oncoheroes Biosciences, Plus Therapeutics Inc., Stemline Therapeutics Inc., BrainChild Bio Inc., Seattle Children’s Therapeutics, Pfizer Inc., Merck & Co Inc., Bristol Myers Squibb Company, Sanofi, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Eli Lilly and Company, Day One Biopharmaceuticals Inc., Biodexa Pharmaceuticals, Cellectar Biosciences Inc., ZIOPHARM Oncology Inc., Y-mAbs Therapeutics Inc., Neonc Technologies Inc.
Get The Full Pediatric Brain Tumors Market Report:
https://www.thebusinessresearchcompany.com/report/pediatric-brain-tumors-global-market-report
Which Region Represents The Largest Share Of The Pediatric Brain Tumors Market?
North America was the largest region in the pediatric brain tumors market in 2025. The regions covered in the pediatric brain tumors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Pediatric Brain Tumors Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/pediatric-brain-tumors-global-market-report
Browse Through More Reports Similar to the Global Pediatric Brain Tumors Market 2026, By The Business Research Company
Overactive Bladder Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/overactive-bladder-treatment-global-market-report
Urinary Tract Infection Treatment Market Report
Bladder Cancer Drugs Market Report
https://www.thebusinessresearchcompany.com/report/bladder-cancer-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model